nach oben

World Journal of Urology

Erschienen in:

01.08.2013 | Topic Paper

Alternative therapies in the management of chronic prostatitis/chronic pelvic pain syndrome

verfasst von: Amin S. Herati, Robert Miles Moldwin

Erschienen in: World Journal of Urology | Ausgabe 4/2013

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Standard medical therapy for Chronic Prostatitis/Chronic Pelvic Pain Syndrome (CP/CPPS) including such agents as nonsteriodal anti-inflammatories, alpha-blockers, antimicrobial therapy, and 5a-reductase inhibitors has not been uniformly effective. The purpose of this review is to focus on the role of alternative therapies available for the management of CP/CPPS.

Methods

We performed a systematic review of the literature for articles published in PubMed up to 2012 pertaining to commonly employed alternative therapies.

Results

The evidence for alternative therapies such as diet and lifestyle modifications, phytotherapy, acupuncture, myofascial physical therapy, and stress management/cognitive behavioral therapy is reviewed.

Conclusion

CP/CPPS often requires a multimodal approach and alternative therapies should be considered as adjuncts in the treatment of refractory CP/CPPS patients.

McNaughton Collins M, Pontari MA, O’Leary MP, Calhoun EA, Santanna J, Landis JR, Kusek JW, Litwin MS (2001) Quality of life is impaired in men with chronic prostatitis: the chronic prostatitis collaborative research network. J Gen Intern Med 16(10):656–662PubMedCrossRef

Schaeffer AJ (2006) Clinical practice. Chronic prostatitis and the chronic pelvic pain syndrome. N Engl J Med 355(16):1690–1698. doi:10.1056/NEJMcp060423 PubMedCrossRef

Shoskes DA, Katz E (2005) Multimodal therapy for chronic prostatitis/chronic pelvic pain syndrome. Curr Urol Rep 6(4):296–299PubMedCrossRef

Nickel JC, Downey J, Ardern D, Clark J, Nickel K (2004) Failure of a monotherapy strategy for difficult chronic prostatitis/chronic pelvic pain syndrome. J Urol 172(2):551–554. doi:10.1097/01.ju.0000131592.98562.16 PubMedCrossRef

Herati AS, Shorter B, Tai J, Lesser M, Moldwin RM (2009) Differences in food sensitivities between female interstitial cystitis/painful bladder syndrome (IC/PBS) and chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) patients. In: American Urological Association Chicago, p 22

Shorter B, Lesser M, Moldwin RM, Kushner L (2007) Effect of comestibles on symptoms of interstitial cystitis. J Urol 178(1):145–152. doi:10.1016/j.juro.2007.03.020 PubMedCrossRef

Richards SC, Scott DL (2002) Prescribed exercise in people with fibromyalgia: parallel group randomised controlled trial. BMJ 325(7357):185PubMedCrossRef

Giubilei G, Mondaini N, Minervini A, Saieva C, Lapini A, Serni S, Bartoletti R, Carini M (2007) Physical activity of men with chronic prostatitis/chronic pelvic pain syndrome not satisfied with conventional treatments–could it represent a valid option? The physical activity and male pelvic pain trial: a double-blind, randomized study. J Urol 177(1):159–165. doi:10.1016/j.juro.2006.08.107 PubMedCrossRef

Sato M, Miyazaki T, Kambe F, Maeda K, Seo H (1997) Quercetin, a bioflavonoid, inhibits the induction of interleukin 8 and monocyte chemoattractant protein-1 expression by tumor necrosis factor-alpha in cultured human synovial cells. J Rheumatol 24(9):1680–1684PubMed

10.

Loschen G, Ebeling L (1991) Inhibition of arachidonic acid cascade by extract of rye pollen. Arzneimittelforschung 41(2):162–167PubMed

11.

Wagenlehner FM, Bschleipfer T, Pilatz A, Weidner W (2011) Pollen extract for chronic prostatitis-chronic pelvic pain syndrome. Urol Clin North Am 38(3):285–292. doi:10.1016/j.ucl.2011.04.004 PubMedCrossRef

12.

Guardia T, Rotelli AE, Juarez AO, Pelzer LE (2001) Anti-inflammatory properties of plant flavonoids. Effects of rutin, quercetin and hesperidin on adjuvant arthritis in rat. Farmaco 56(9):683–687PubMedCrossRef

13.

Wagenlehner FM, Schneider H, Ludwig M, Schnitker J, Brahler E, Weidner W (2009) A pollen extract (Cernilton) in patients with inflammatory chronic prostatitis-chronic pelvic pain syndrome: a multicentre, randomised, prospective, double-blind, placebo-controlled phase 3 study. Eur Urol 56(3):544–551. doi:10.1016/j.eururo.2009.05.046 PubMedCrossRef

14.

Elist J (2006) Effects of pollen extract preparation Prostat/Poltit on lower urinary tract symptoms in patients with chronic nonbacterial prostatitis/chronic pelvic pain syndrome: a randomized, double-blind, placebo-controlled study. Urology 67(1):60–63. doi:10.1016/j.urology.2005.07.035 PubMedCrossRef

15.

Buck AC, Rees RW, Ebeling L (1989) Treatment of chronic prostatitis and prostatodynia with pollen extract. Br J Urol 64(5):496–499PubMedCrossRef

16.

Monden K, Tsugawa M, Ninomiya Y, Ando E, Kumon H (2002) A Japanese version of the National Institutes of Health Chronic Prostatitis Symptom Index (NIH-CPSI, Okayama version) and the clinical evaluation of cernitin pollen extract for chronic non-bacterial prostatitis. Nihon Hinyokika Gakkai Zasshi 93(4):539–547PubMed

17.

Shoskes DA, Zeitlin SI, Shahed A, Rajfer J (1999) Quercetin in men with category III chronic prostatitis: a preliminary prospective, double-blind, placebo-controlled trial. Urology 54(6):960–963PubMedCrossRef

18.

Paubert-Braquet M, Mencia Huerta JM, Cousse H, Braquet P (1997) Effect of the lipidic lipidosterolic extract of Serenoa repens (Permixon) on the ionophore A23187-stimulated production of leukotriene B4 (LTB4) from human polymorphonuclear neutrophils. Prostaglandins Leukot Essent Fatty Acids 57(3):299–304PubMedCrossRef

19.

Kaplan SA, Volpe MA, Te AE (2004) A prospective, 1-year trial using saw palmetto versus finasteride in the treatment of category III prostatitis/chronic pelvic pain syndrome. J Urol 171(1):284–288. doi:10.1097/01.ju.0000101487.83730.80 PubMedCrossRef

20.

Plosker GL, Brogden RN (1996) Serenoa repens (Permixon). A review of its pharmacology and therapeutic efficacy in benign prostatic hyperplasia. Drugs Aging 9(5):379–395PubMedCrossRef

21.

Weisser H, Tunn S, Behnke B, Krieg M (1996) Effects of the sabal serrulata extract IDS 89 and its subfractions on 5 alpha-reductase activity in human benign prostatic hyperplasia. Prostate 28(5):300–306. doi:10.1002/(SICI)1097-0045(199605)28:5<300:AID-PROS5>3.0.CO;2-F PubMedCrossRef

22.

Nickel JC, Downey J, Pontari MA, Shoskes DA, Zeitlin SI (2004) A randomized placebo-controlled multicentre study to evaluate the safety and efficacy of finasteride for male chronic pelvic pain syndrome (category IIIA chronic nonbacterial prostatitis). BJU Int 93(7):991–995. doi:10.1111/j.1464-410X.2003.04766.x PubMedCrossRef

23.

Schaeffer AJ (2005) A randomized placebo-controlled multicentre study to evaluate the safety and efficacy of finasteride for male chronic pelvic pain syndrome (category IIIA chronic nonbacterial prostatitis). J Urol 173(3):845

24.

Chen R, Nickel JC (2003) Acupuncture ameliorates symptoms in men with chronic prostatitis/chronic pelvic pain syndrome. Urology 61(6):1156–1159 discussion 1159PubMedCrossRef

25.

Lee SW, Liong ML, Yuen KH, Leong WS, Chee C, Cheah PY, Choong WP, Wu Y, Khan N, Choong WL, Yap HW, Krieger JN (2008) Acupuncture versus sham acupuncture for chronic prostatitis/chronic pelvic pain. Am J Med 121(1):79 e71–79 e77. doi:10.1016/j.amjmed.2007.07.033 CrossRef

26.

Lee SH, Lee BC (2009) Electroacupuncture relieves pain in men with chronic prostatitis/chronic pelvic pain syndrome: three-arm randomized trial. Urology 73(5):1036–1041. doi:10.1016/j.urology.2008.10.047 PubMedCrossRef

27.

Zermann DH, Ishigooka M, Doggweiler R, Schmidt RA (1999) Neurourological insights into the etiology of genitourinary pain in men. J Urol 161(3):903–908PubMedCrossRef

28.

Hetrick DC, Ciol MA, Rothman I, Turner JA, Frest M, Berger RE (2003) Musculoskeletal dysfunction in men with chronic pelvic pain syndrome type III: a case-control study. J Urol 170(3):828–831. doi:10.1097/01.ju.0000080513.13968.56 PubMedCrossRef

29.

Clemens JQ, Nadler RB, Schaeffer AJ, Belani J, Albaugh J, Bushman W (2000) Biofeedback, pelvic floor re-education, and bladder training for male chronic pelvic pain syndrome. Urology 56(6):951–955PubMedCrossRef

30.

Cornel EB, van Haarst EP, Schaarsberg RW, Geels J (2005) The effect of biofeedback physical therapy in men with chronic pelvic pain syndrome type III. Eur Urol 47(5):607–611. doi:10.1016/j.eururo.2004.12.014 PubMedCrossRef

31.

Lavelle ED, Lavelle W, Smith HS (2007) Myofascial trigger points. Anesthesiol Clin 25(4):841-851, vii-iii. doi:10.1016/j.anclin.2007.07.003

32.

Anderson RU, Sawyer T, Wise D, Morey A, Nathanson BH (2009) Painful myofascial trigger points and pain sites in men with chronic prostatitis/chronic pelvic pain syndrome. J Urol 182(6):2753–2758. doi:10.1016/j.juro.2009.08.033 PubMedCrossRef

33.

Anderson RU, Wise D, Sawyer T, Chan C (2005) Integration of myofascial trigger point release and paradoxical relaxation training treatment of chronic pelvic pain in men. J Urol 174(1):155–160. doi:10.1097/01.ju.0000161609.31185.d5 PubMedCrossRef

34.

Anderson RU, Wise D, Sawyer T, Chan CA (2006) Sexual dysfunction in men with chronic prostatitis/chronic pelvic pain syndrome: improvement after trigger point release and paradoxical relaxation training. J Urol 176(4 Pt 1):1534–1538. doi:10.1016/j.juro.2006.06.010 discussion 1538-1539PubMedCrossRef

35.

FitzGerald MP, Anderson RU, Potts J, Payne CK, Peters KM, Clemens JQ, Kotarinos R, Fraser L, Cosby A, Fortman C, Neville C, Badillo S, Odabachian L, Sanfield A, O’Dougherty B, Halle-Podell R, Cen L, Chuai S, Landis JR, Mickelberg K, Barrell T, Kusek JW, Nyberg LM (2009) Randomized multicenter feasibility trial of myofascial physical therapy for the treatment of urological chronic pelvic pain syndromes. J Urol 182(2):570–580. doi:10.1016/j.juro.2009.04.022 PubMedCrossRef

36.

Anderson R, Wise D, Sawyer T, Nathanson BH (2011) Safety and effectiveness of an internal pelvic myofascial trigger point wand for urologic chronic pelvic pain syndrome. Clin J Pain 27(9):764–768. doi:10.1097/AJP.0b013e31821dbd76 PubMedCrossRef

37.

Clemens JQ, Brown SO, Calhoun EA (2008) Mental health diagnoses in patients with interstitial cystitis/painful bladder syndrome and chronic prostatitis/chronic pelvic pain syndrome: a case/control study. J Urol 180(4):1378–1382. doi:10.1016/j.juro.2008.06.032 PubMedCrossRef

38.

Walz J, Perrotte P, Hutterer G, Suardi N, Jeldres C, Benard F, Valiquette L, Karakiewicz PI (2007) Impact of chronic prostatitis-like symptoms on the quality of life in a large group of men. BJU Int 100(6):1307–1311. doi:10.1111/j.1464-410X.2007.07250.x PubMedCrossRef

39.

Ullrich PM, Turner JA, Ciol M, Berger R (2005) Stress is associated with subsequent pain and disability among men with nonbacterial prostatitis/pelvic pain. Ann Behav Med 30(2):112–118. doi:10.1207/s15324796abm3002_3 PubMedCrossRef

40.

Miller HC (1988) Stress prostatitis. Urology 32(6):507–510PubMedCrossRef

41.

Nickel JC, Mullins C, Tripp DA (2008) Development of an evidence-based cognitive behavioral treatment program for men with chronic prostatitis/chronic pelvic pain syndrome. World J Urol 26(2):167–172. doi:10.1007/s00345-008-0235-6 PubMedCrossRef

42.

Tripp DA, Nickel JC, Katz L (2011) A feasibility trial of a cognitive-behavioural symptom management program for chronic pelvic pain for men with refractory chronic prostatitis/chronic pelvic pain syndrome. Can Urol Assoc J 5(5):328–332. doi:10.5489/cuaj.10201 PubMedCrossRef

43.

Yavascaoglu I, Oktay B, Simsek U, Ozyurt M (1999) Role of ejaculation in the treatment of chronic non-bacterial prostatitis. Int J Urol 6(3):130–134PubMedCrossRef

Titel: Alternative therapies in the management of chronic prostatitis/chronic pelvic pain syndrome
verfasst von: Amin S. Herati
Robert Miles Moldwin
Publikationsdatum: 01.08.2013
Verlag: Springer Berlin Heidelberg
Erschienen in: World Journal of Urology / Ausgabe 4/2013
Print ISSN: 0724-4983
Elektronische ISSN: 1433-8726
DOI: https://doi.org/10.1007/s00345-013-1097-0

Neu im Fachgebiet Urologie

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Fehlerkultur in der Medizin – Offenheit zählt!

28.05.2024 Internistische Arzneimitteltherapie Podcast

Darüber reden und aus Fehlern lernen, sollte das Motto in der Medizin lauten. Und zwar nicht nur im Sinne der Patientensicherheit. Eine negative Fehlerkultur kann auch die Behandelnden ernsthaft krank machen, warnt Prof. Dr. Reinhard Strametz. Ein Plädoyer und ein Leitfaden für den offenen Umgang mit kritischen Ereignissen in Medizin und Pflege.

ADT zur Radiatio nach Prostatektomie: Wenn, dann wohl länger

24.05.2024 Prostatakarzinom Nachrichten

Welchen Nutzen es trägt, wenn die Strahlentherapie nach radikaler Prostatektomie um eine Androgendeprivation ergänzt wird, hat die RADICALS-HD-Studie untersucht. Nun liegen die Ergebnisse vor. Sie sprechen für länger dauernden Hormonentzug.

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

Update Urologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Alternative therapies in the management of chronic prostatitis/chronic pelvic pain syndrome

Abstract

Purpose

Methods

Results

Conclusion

Neu im Fachgebiet Urologie

Costims – das nächste heiße Ding in der Krebstherapie?

Fehlerkultur in der Medizin – Offenheit zählt!

ADT zur Radiatio nach Prostatektomie: Wenn, dann wohl länger

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

Update Urologie

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2013

Male chronic pelvic pain syndrome and the role of interdisciplinary pain management

Response by authors re: Differentiation of oncocytoma and renal cell carcinoma in small renal masses (<4 cm): the role of 4-phase computerized tomography

Understanding chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS)

Sexual dysfunction in chronic prostatitis/chronic pelvic pain syndrome

Etiology of chronic prostatitis/chronic pelvic pain syndrome: psychoimmunoneurendocrine dysfunction (PINE syndrome) or just a really bad infection?

Role of pelvic phased array magnetic resonance imaging in staging of prostate cancer specifically in patients diagnosed with clinically locally advanced tumours by digital rectal examination

Neu im Fachgebiet Urologie

Costims – das nächste heiße Ding in der Krebstherapie?

Fehlerkultur in der Medizin – Offenheit zählt!

ADT zur Radiatio nach Prostatektomie: Wenn, dann wohl länger

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

Update Urologie